Directa Plus PLC (AIM:DCTA, OTC:DTPKF), the producer of graphene nanoplatelets-based products, secured an Italian patent for its G+ technology in filtration applications.
The patent covers the use of the company’s G+ pristine graphene nanoplatelets applied to textile substrates for high bacterial filtration efficiency media for filtration applications.
G+ applied to textile substrates provides proven antibacterial and antiviral performance, including anti-SARS-CoV-2, Directa Plus said in a statement.
The target filtration market applications cover both medical and industrial use.
"The grant of a patent for a new market vertical demonstrates the speed with which we can enter existing high potential markets to supply innovative new products,” said founder and CEO Giulio Cesareo.
“The international filtration markets are large and we believe that there will be significant demand for proven antimicrobial products which we aim to launch quickly with our industrial partners."
Following the grant of the Italian patent, the company's IP portfolio now comprises 20 patent families with 73 patents granted and 28 patents pending.